)
Minerva Neurosciences (NERV) investor relations material
Minerva Neurosciences Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
The annual meeting will be held virtually on June 3, 2026, with full participation rights for shareholders online.
Six key proposals are up for vote, including director elections, charter amendments, executive compensation, and auditor ratification.
Only shareholders of record as of April 9, 2026, may vote; quorum is a majority of shares outstanding.
Voting can be done online, by phone, by mail, or during the meeting; broker non-votes apply to non-routine matters.
Voting matters and shareholder proposals
Election of two Class III directors to serve until 2029.
Amendment to the certificate of incorporation to allow officer exculpation under Delaware law.
Amendment to eliminate the exclusive forum provision from the charter.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes (board recommends annual).
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Shareholder proposals and director nominations for 2027 must comply with SEC and bylaw deadlines.
Board of directors and corporate governance
Board consists of six members divided into three classes with staggered three-year terms.
Majority of directors are independent per Nasdaq standards; CEO serves as Board Chair, with a lead independent director appointed.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.
Board met ten times in 2025; committee meetings held as required.
Code of Ethics and policies on insider trading, hedging, and pledging are in place.
- Registering up to $200M in securities to fund CNS drug development and corporate growth.NERV
Registration Filing11 Mar 2026 - 2025 net loss driven by non-cash charges; Phase 3 trial for roluperidone set for Q2 2026.NERV
Q4 202511 Mar 2026 - Roluperidone targets negative symptoms in schizophrenia, with a pivotal phase III trial underway.NERV
The Citizens Life Sciences Conference 202610 Mar 2026 - Roluperidone advances as a leading candidate for negative symptoms, with robust data and funding.NERV
KOL event3 Feb 2026 - Q3 2025 net loss of $2.7M; $80M raised for Phase 3 roluperidone trial, up to $120M more possible.NERV
Q3 202512 Jan 2026 - Q1 2025 net loss narrowed to $3.8M; regulatory and funding risks remain significant.NERV
Q1 202512 Jan 2026 - Q3 net income surged on a $26.6M royalty gain, but regulatory and Nasdaq risks persist.NERV
Q3 202412 Jan 2026 - Q2 net loss was $8.2M, R&D costs rose, and cash reserves dropped to $31M.NERV
Q2 202412 Jan 2026 - Registering 94.6M shares for resale, with up to $120M for pivotal schizophrenia trial funding.NERV
Registration Filing23 Dec 2025
Next Minerva Neurosciences earnings date
Next Minerva Neurosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage